{"title":"结核分枝杆菌破坏宿主因子:宿主定向治疗的潜在靶点。","authors":"Rashi Kalra, Drishti Tiwari, Hedwin Kitdorlang Dkhar, Ella Bhagyaraj, Rakesh Kumar, Anshu Bhardwaj, Pawan Gupta","doi":"10.1080/08830185.2021.1990277","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Despite new approaches in the diagnosis and treatment of tuberculosis (TB), it continues to be a major health burden. Several immunotherapies that potentiate the immune response have come up as adjuncts to drug therapies against drug resistant TB strains; however, there needs to be an urgent appraisal of host specific drug targets for improving their clinical management and to curtail disease progression. Presently, various host directed therapies (HDTs) exist (repurposed drugs, nutraceuticals, monoclonal antibodies and immunomodulatory agents), but these mostly address molecules that combat disease progression.</p><p><strong>Areas covered: </strong>The current review discusses major <i>Mycobacterium tuberculosis</i> (<i>M. tuberculosis</i>) survival paradigms inside the host and presents a plethora of host targets subverted by <i>M. tuberculosis</i> which can be further explored for future HDTs. The host factors unique to <i>M. tuberculosis</i> infection (in humans) have also been identified through an <i>in-silico</i> interaction mapping.</p><p><strong>Expert opinion: </strong>HDTs could become the next-generation adjunct therapies in order to counter antimicrobial resistance and virulence, as well as to reduce the duration of existing TB treatments. However, current scientific efforts are largely directed toward combatants rather than host molecules co-opted by <i>M. tuberculosis</i> for its survival. This might drive the immune system to a hyper-inflammatory condition; therefore, we emphasize that host factors subverted by <i>M. tuberculosis</i>, and their subsequent neutralization, must be considered for development of better HDTs.</p>","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":"42 1","pages":"43-70"},"PeriodicalIF":4.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Host factors subverted by <i>Mycobacterium tuberculosis:</i> Potential targets for host directed therapy.\",\"authors\":\"Rashi Kalra, Drishti Tiwari, Hedwin Kitdorlang Dkhar, Ella Bhagyaraj, Rakesh Kumar, Anshu Bhardwaj, Pawan Gupta\",\"doi\":\"10.1080/08830185.2021.1990277\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Despite new approaches in the diagnosis and treatment of tuberculosis (TB), it continues to be a major health burden. Several immunotherapies that potentiate the immune response have come up as adjuncts to drug therapies against drug resistant TB strains; however, there needs to be an urgent appraisal of host specific drug targets for improving their clinical management and to curtail disease progression. Presently, various host directed therapies (HDTs) exist (repurposed drugs, nutraceuticals, monoclonal antibodies and immunomodulatory agents), but these mostly address molecules that combat disease progression.</p><p><strong>Areas covered: </strong>The current review discusses major <i>Mycobacterium tuberculosis</i> (<i>M. tuberculosis</i>) survival paradigms inside the host and presents a plethora of host targets subverted by <i>M. tuberculosis</i> which can be further explored for future HDTs. The host factors unique to <i>M. tuberculosis</i> infection (in humans) have also been identified through an <i>in-silico</i> interaction mapping.</p><p><strong>Expert opinion: </strong>HDTs could become the next-generation adjunct therapies in order to counter antimicrobial resistance and virulence, as well as to reduce the duration of existing TB treatments. However, current scientific efforts are largely directed toward combatants rather than host molecules co-opted by <i>M. tuberculosis</i> for its survival. This might drive the immune system to a hyper-inflammatory condition; therefore, we emphasize that host factors subverted by <i>M. tuberculosis</i>, and their subsequent neutralization, must be considered for development of better HDTs.</p>\",\"PeriodicalId\":14333,\"journal\":{\"name\":\"International Reviews of Immunology\",\"volume\":\"42 1\",\"pages\":\"43-70\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Reviews of Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/08830185.2021.1990277\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Reviews of Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08830185.2021.1990277","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Host factors subverted by Mycobacterium tuberculosis: Potential targets for host directed therapy.
Introduction: Despite new approaches in the diagnosis and treatment of tuberculosis (TB), it continues to be a major health burden. Several immunotherapies that potentiate the immune response have come up as adjuncts to drug therapies against drug resistant TB strains; however, there needs to be an urgent appraisal of host specific drug targets for improving their clinical management and to curtail disease progression. Presently, various host directed therapies (HDTs) exist (repurposed drugs, nutraceuticals, monoclonal antibodies and immunomodulatory agents), but these mostly address molecules that combat disease progression.
Areas covered: The current review discusses major Mycobacterium tuberculosis (M. tuberculosis) survival paradigms inside the host and presents a plethora of host targets subverted by M. tuberculosis which can be further explored for future HDTs. The host factors unique to M. tuberculosis infection (in humans) have also been identified through an in-silico interaction mapping.
Expert opinion: HDTs could become the next-generation adjunct therapies in order to counter antimicrobial resistance and virulence, as well as to reduce the duration of existing TB treatments. However, current scientific efforts are largely directed toward combatants rather than host molecules co-opted by M. tuberculosis for its survival. This might drive the immune system to a hyper-inflammatory condition; therefore, we emphasize that host factors subverted by M. tuberculosis, and their subsequent neutralization, must be considered for development of better HDTs.
期刊介绍:
This review journal provides the most current information on basic and translational research in immunology and related fields. In addition to invited reviews, the journal accepts for publication articles and editorials on relevant topics proposed by contributors. Each issue of International Reviews of Immunology contains both solicited and unsolicited review articles, editorials, and ''In-this-Issue'' highlights. The journal also hosts reviews that position the authors'' original work relative to advances in a given field, bridging the gap between annual reviews and the original research articles.
This review series is relevant to all immunologists, molecular biologists, microbiologists, translational scientists, industry researchers, and physicians who work in basic and clinical immunology, inflammatory and allergic diseases, vaccines, and additional topics relevant to medical research and drug development that connect immunology to disciplines such as oncology, cardiovascular disease, and metabolic disorders.
Covered in International Reviews of Immunology: Basic and developmental immunology (innate and adaptive immunity; inflammation; and tumor and microbial immunology); Clinical research (mechanisms of disease in man pertaining to infectious diseases, autoimmunity, allergy, oncology / immunology); and Translational research (relevant to biomarkers, diagnostics, vaccines, and drug development).